Key statistics
As of last trade Exelixis Inc (EXEL:NSQ) traded at 43.43, -12.48% below its 52-week high of 49.62, set on Jun 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 43.97 |
|---|---|
| High | 44.28 |
| Low | 43.30 |
| Bid | 43.42 |
| Offer | 43.44 |
| Previous close | 43.95 |
| Average volume | 2.88m |
|---|---|
| Shares outstanding | 268.11m |
| Free float | 261.87m |
| P/E (TTM) | 18.50 |
| Market cap | 11.78bn USD |
| EPS (TTM) | 2.38 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 19:26 GMT.
More ▼
Press releases
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
- Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
- Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
More ▼
